Literature DB >> 10734306

Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer.

J O Bay1, B Choufi, C Pomel, J Dauplat, X Durando, O Tournilhac, P Travade, R Plagne, D Blaise.   

Abstract

A 33-year-old woman developed progressive ovarian cancer resistant to classical chemotherapy agents. We performed a bone marrow allograft after a myeloablative regimen. During hematological recovery, she developed acute graft-versus-host disease (GVHD). From this time her tumor diminished progressively. One year post transplant she has limited chronic liver GVHD and is still free of disease. The complete remission of advanced ovarian cancer was probably related to the GVHD which might therefore provide a new treatment option for this disease.

Entities:  

Mesh:

Year:  2000        PMID: 10734306     DOI: 10.1038/sj.bmt.1702206

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

Review 1.  Cellular immune therapy for refractory cancers: novel therapeutic strategies.

Authors:  Karen K Ballen; Gerald Colvin; Bimalangshu R Dey; David Porter; Peter Westervelt; Thomas R Spitzer; Peter J Quesenberry
Journal:  Exp Hematol       Date:  2005-12       Impact factor: 3.084

Review 2.  Low dose total body irradiation followed by allogeneic lymphocyte infusion for refractory hematologic malignancy--an updated review.

Authors:  Karen K Ballen; Gerald Colvin; David Porter; Peter J Quesenberry
Journal:  Leuk Lymphoma       Date:  2004-05

Review 3.  Allogeneic stem cell transplantation for the treatment of advanced solid tumors.

Authors:  Marco Bregni; Massimo Bernardi; Fabio Ciceri; Jacopo Peccatori
Journal:  Springer Semin Immunopathol       Date:  2004-09-11

4.  Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors.

Authors:  Cristian Carvallo; Richard Childs
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

5.  Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma.

Authors:  D J Gottlieb; Y-C Li; I Lionello; S Tanzarella; M Marangolo; K F Bradstock; V Russo; C Traversari
Journal:  Br J Cancer       Date:  2006-07-04       Impact factor: 7.640

6.  The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells.

Authors:  Christoph A Klein; Martina Wilke; Jos Pool; Corine Vermeulen; Els Blokland; Elke Burghart; Sabine Krostina; Nicole Wendler; Bernward Passlick; Gert Riethmüeller; Els Goulmy
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

7.  m6A RNA methylation regulators were associated with the malignancy and prognosis of ovarian cancer.

Authors:  Cheng Zhang; JinHui Liu; Hongyu Guo; Dandan Hong; Jing Ji; Qin Zhang; Qun Guan; Qingling Ren
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.